Document is current
Any future updates will be listed below
-
Authors
Saito, Yukihiro https://orcid.org/0000-0001-7454-3102
Nakamura, Kazufumi
Katanosaka, Yuki
Iida, Toshihiro
Kusumoto, Dai
Sato, Ryushi
Adachi, Riki
Shimizu, Satoshi
Kurokawa, Junko
Akagi, Satoshi
Yoshida, Masashi
Miyoshi, Toru
Morita, Hiroshi
Naruse, Keiji
Nishida, Mikako
Udono, Heiichiro
Zhang, Jianhua
Yuasa, Shinsuke
Kamp, Timothy J.
Ito, Hiroshi
-
Funding
Funding for this research was provided by:
Japan Society for the Promotion of Science (JP21K16057, JP23K07508)
Japan Foundation for Applied Enzymology (Japan Foundation for Applied Enzymology)
Bristol Myers Squibb Japan (Bristol Myers Squibb Japan)
Uehara Memorial Foundation (Uehara Memorial Foundation)
NIH (U01HL134764)
National Science Foundation Engineering Research Center for Cell Manufacturing Technologies (NSF EEC-1648035)
Suzuken Memorial Foundation (Suzuken Memorial Foundation)
- License Information
-
More Information
Article History
Received: 13 June 2023
Accepted: 1 September 2025
First Online: 26 September 2025
Declarations
:
: This study was approved by the Ethics Committee of Okayama University Graduate School of Medicine, Density, and Pharmaceutical Sciences (Title: Research on the establishment of iPS cells from patients with human cardiovascular diseases and disease analysis using these cells, approval number: Ge299, approval date: 01/15/2021), and written informed consent was obtained from healthy subjects before collection of their PBMCs. This study conformed to the principles outlined in the Declaration of Helsinki. The HES3 hESC line (RRID: CVCL_7158) was originally derived by ES Cell International Pte Ltd. in Singapore. The derivation was conducted under an approved human subjects protocols, and informed consent was obtained from the donor as stated in the hPSCreg–Human Pluripotent Stem Cell Registry entry for the ESIBIe003-A cell line ().
: Not applicable.
: The authors declare no conflicts of interest.
